GLYcoPROFILE® makes the news! GLYcoPROFILE was used by Seqens and reported in In-Cosmetics 2019

GLYcoDiag is pround to report that its technology of GLYcoPROFILE® have recently allowed to highlight glycobiological interactions of the cosmetic active Glycuron™ 2.78, developed by Seqens. Thanks to the curious and innovative team spirit of Seqens and their kind attention for mentionning GLYcoDiag through their communication.
Learn more about GLYcoPROFILE

Tulipa gesneriana agglutinin (TXLC-I) a Gal/GalNAc lectin is now available

Tulipa gesneriana agglutinin (TxLC-I) is isolated from tulip bulbs and purified by affinity column chromatography on a Fetuin-Sepharose 4B gel. TxLC-I was originally described as a tetramer of four identical subunits of 28 kDa. Then, after amino acid sequence analyses, this subunit seems to be partialy cleaved into two smaller polypeptides of approximatively 14 kDa each. TxLC-I have a Gal/GalNAc binding domain and show highest affinity to triantennary carbohydrates and diantennary oligosaccharide with Gal residues.
GLYcoDiag lectin TxLC-I v1.2

GLYcoDiag participate to a research collaboration aimed at the study of new lectin ligands

H. Prasch, C. Hojnik, T. K. Lindhorst, B. Didak, L. Landemarre, T. M. Wrodnigg. New lectin ligands: Testing of Amadori rearrangement products with a series of mannoside-specific lectins, Carbohydr. Res., 2019, accepted manuscript (DOI: 10.1016/j.carres.2019.01.010).

C-glycosyl-type compounds derived from an Amadori rearrangement: D-glycero-D-galacto-aldoheptose and the two corresponding multivalent BSA neoglycoproteins, were evaluated as ligands on a series of seven relevant mannose-specific lectins. The evaluation of the IC50-value (concentration corresponding to 50% of inhibition) of the compounds has been evaluated. Multivalency turned out to effectively influence ligand selectivity and lectin binding.

GLYcoDiag participate to a research collaboration aimed at the study of sialidases and multivalent thiosialosides

Brissonnet, Y., Assailly, C. Saumonneau, A., Bouckaert, J., Maillasson, M., Petito, C., Roubinet, B., Didak, B., Landemarre, L., Bridot, C., Blossey, R., Deniaud, D., Yan, X., Bernard, J. Tellier, C., Grandjean, C., Daligault, F., Gouin, S. G., Multivalent thiosialosides and their synergistic interaction with pathogenic sialidases, Chem. Eur. J., accepted article (DOI: 10.1002/chem.201805790)

Sialidases (SA) hydrolyze sialyl residues from glycoconjugates of the eukaryotic cell surface and are virulence factors expressed by pathogenic bacteria, viruses and parasites. The catalytic domain of SA are often flanked with carbohydrate-binding module(s) previously shown to bind sialosides and to enhance enzymatic catalytic efficiency. Here we designed non-hydrolyzable multivalent thiosialosides as probes and inhibitors of V. cholerae, T. cruzi and S. pneumoniae (NanA) sialidases. NanA was truncated from the catalytic and lectinic domains (NanA-L and NanA-C) to probe their respective roles when interacting with sialylated surfaces and the synthetically designed di-, and polymeric thiosialosides. NanA-L domain was shown to fully drive NanA binding, improving affinity for the thiosialylated surface and compounds by more than two orders of magnitude. Importantly, each thiosialoside grafted onto the polymer was also shown to reduce NanA and NanA-C catalytic activity with a 3000-fold higher efficiency compared to the monovalent thiosialoside reference. These results extend the concept of multivalency for designing potent bacterial and parasitic sialidase inhibitors.

GLYcoDiag will be attending In-cosmetics, Paris, 2-4 april 2019

Heading into its 30th edition in 2019, in-cosmetics Global is the leading event for personal care ingredients. The exhibition brings together personal care ingredients suppliers (exhibitors) with finished product manufacturers (visitors), each looking to network, learn about future trends, and discover new products.

We are pleased to invite you to meet us on our booth and discuss about our glycosciences and microbiote services and innovation strategies:

We provide added value in terms of innovation, originality and scientific proofs for the research and development of “glycoactives”

– Our technology platform GLYcoPROFILE® is intended for biological activities prediction through the study of skin cells, microbiote and involvement of glycosylated molecules in the natural glycobiological interactions relevant for cosmetics applications.

– High throughput and/or alternative methods aimed to study microbiote activities of products. Activities comparison on various strains (either isolated or mixed in co-culture models. Prebiotics or, on the contrary, anti-microbials effects.

– Microbiote / glycobiological interactions studies. As a research company specialized in Glycosciences, we have a strong know-how regarding the interactions between microbiote and cutaneous cells mediated by lectins (lectins-like)-glycoconjugates recognitions.

GLYcoDiag is proud to announce its participation as beneficiary to a new H2020-MSCA-ITN synBIOcarb

synBIOcarb “Synthetic biology of carbohydrate-binding proteins: engineering protein-carbohydrate interactions for diagnostics and cell targeting”

The synBIOcarb European Training Network brings together a diverse team of chemists, structural biologists, biophysicists, cell biologists and protein engineers who are pioneering the development of Synthetic Glycobiology, and four SMEs that are leading industrial innovation in glycoscience and protein engineering.

Together, we will provide 15 early stage researchers (ESRs) with advanced scientific training in enabling technologies that underpin the development and exploitation of glycoscience for diagnostics and targeted drug delivery. Each ESR will contribute to one, or more, of four thematic Work Packages, that have been designed to progress the state-of-the-art in Synthetic Glycobiology.

Practical scientific training will be complemented by a coordinated programme of industry-relevant transferable skills, that will prepare the ESRs for future careers in the medical technologies sector.

Currently a position for an early stage researcher is open at GLYcoDiag:

ESR Position:  Development of lectin kit for quality control in production of recombinant glycoprotein

Applications are invited for a 36 months position as early-stage researcher (ESR) to work on the Marie Skłodowska-Curie Innovative Training Network synBIOcarb (Synthetic biology of carbohydrate-binding proteins: engineering protein-carbohydrate interactions for diagnostics and cell targeting; https://synbiocarb.science ).

The research, which will be carried out at GLYcoDiag, Orléans, France revolves around the development of a lectin chip covering the detection of the major undesirable glycan structures in therapeutic glycoproteins to allow real-time monitoring and control. We will clone, express and purify several lectins that have been reported in the literature to present the specificity toward glycan epitopes that may rise to unwanted immune response in production of glycosylated biopharmaceutical. Technology for biosensors will be investigated with partners. 

The successful candidate will participate in the network’s training activities and work placements at the laboratories of the participating academic and industrial teams (secondments planned in three other laboratories located in Denmark, Slovakia and France). Regular meetings and workshops within the EU-funded synBIOcarb International Training Network will supplement the training and support provided at GLYcoDiag. Moreover, The early-stage researcher will be recruited as PhD Student at GLYcoDiag and will be registered at the doctoral school of University of Orléans.

Requirements

Applicants should meet the following eligibility criteria:

– Have a Diploma and/or a Master Degree in biochemistry/organic chemistry. Previous knowledge or experience in glycobiology is desirable.

– Have less than 4 years research experience at the signature of the contract (measured from the time the Master’s degree has been obtained).

– Not have a PhD already.

– Not have resided or carried out main activity in France for more than 12 months in the last 3 years immediately prior to the reference recruitment date.

– Excellent knowledge of the English language (spoken and written / proficiency level)

– A particular experience and/or interest for applied research and working in environment of small biotech company would be an advantage.

Benefits

The ESR will be contractually employed by GLYcoDiag and will be covered under the social security scheme. He or she will receive a Monthly Living Allowance plus a Mobility Allowance compliant with the applicable EC Marie Skłodowska-Curie Actions-ITN general conditions.

Application procedure:

Candidates should submit a CV, cover letter and the names and contact details of at least 3 references by e-mail to contact@glycodiag.com indicating reference nº ITN1810 in the subject.